- (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor Business Wire
- FDA approves innovative T cell immunotherapy for rare soft-tissue cancer STAT
- FDA signs off on Adaptimmune’s Tecelra as the first engineered cell therapy for a solid tumor FiercePharma
- US FDA Approves Adaptimmune’s Gene Therapy for Rare Cancer U.S. News & World Report
- Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor Morningstar
